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988 LETTERS TO THE EDITORDetection of IL-36g through
noninvasive tape stripping reliably
discriminates psoriasis from atopic
eczemaTo the Editor:
Inflammatory skin reactions, regardless of their distinct
underlying pathophysiologic mechanisms, can often present
with similar morphology. Although typical eczema and lesions
of plaque psoriasis are easily distinguishable by experienced
dermatologists, these 2 diseases often cause diagnostic difficulties
when inflammation is minimal or located in certain anatomical
regions, including flexures, the scalp, auricular or palmoplantar
areas. In these cases diagnosis can be problematic, in particular in
the primary care setting, where misdiagnosis can lead to delayed
appropriate treatment, overuse of antibiotics, or both.
Histopathology, which is the current gold standard in diagnosing
challenging cases, is invasive, costly, and often unavailable in the
primary care setting. Furthermore, histopathologic differentiation
of psoriasis from eczema in some anatomical localizations, such as
the palmoplantar region, is difficult.1 Unfortunately, there are also
no reliable blood-derived diagnostic biomarkers that cover thewide
range of clinical phenotypes and disease severities, and although
RNA signatures from lesional skin biopsy specimens have been
described for atopic dermatitis (AD) and psoriasis, mRNA
analysis can be costly and labor intensive. Therefore a simple,
noninvasive, and reliable diagnostic approach would be of great
clinical benefit. To address this need, this study uses a noninvasive,
tape-stripping, and ELISA-based approach to investigate potential
protein biomarkers that are able to discriminate eczematous from
psoriatic inflammation presenting with a range of severities.
Because the epidermis is a significant source of chemokines,
inflammatory lesions from patients with psoriasis and those with
ADwere sampled initially bymeans of tape stripping and analyzed
for the neutrophil-recruiting chemokines CXCL1 and IL-8, as well
as CCL20, which recruits IL-17/IL-22–producing cells (see the
Methods section in this article’s Repository at www.jacionline.org
for detailed methodology).2 Although these chemokines were
found at significantly greater levels in tape-stripping samples
from lesions of patients with psoriasis compared with those with
AD, receiver operating characteristic (ROC) curve analysis indi-
cated that they would not be ideal as strong discriminators of the
2 conditions (IL-8: area under the curve [AUC], 0.83; SE,
0.0523; 95% CI, 0.726-0.931; CXCL1: AUC, 0.796; SE, 0.049;
95% CI, 0.7-0.891 [Fig 1, B]; CCL20: AUC, 0.82; SE, 0.045;
95% CI, 0.731-0.905). For all 3 chemokines, no or very low levels
of protein were detected in healthy and nonlesional samples.
Because high levels of IL-36g mRNA and protein have been
reported in lesions of patients with psoriasis,3,4 IL-36g from tape
samples was quantitated through use of a novel in-house
sandwich ELISA (see the Methods section in this article’s Online
Repository). IL-36g showed a trend for increased levels in
patients with AD compared with levels seen in nonlesional or
healthy skin (mean, 71/13.5/57.5 pg/mg total protein,
respectively). However, IL-36g levels within psoriatic lesions 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. All rights reserved. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).were significantly greater than those in AD lesions (mean, 719
vs 71 pg/mg total protein; Fig 1, A). No difference in IL-36g
expression was observed in healthy versus nonlesional psoriatic
skin taken from ventral forearm areas.
A ROC curve (AUC, 0.987; SE, 0.0114; 95% CI, 0.965-1.01)
was plotted to determine the sensitivity and specificity of IL-36g
in a diagnostic approach (Fig 1, A). At an optimal cutoff level of
214 pg/mg total protein (Youden index, 0.944), IL-36g specificity
was calculated as 100% (95% CI, 90% to 100%), and sensitivity
was calculated as 94.44% (95% CI, 84.61% to 98.84%). This
suggests that IL-36g has an excellent potential as a diagnostic
marker for psoriatic inflammation. When compared with
CXCL1, the increased expression of IL-36g is far more
consistent, being found across all patients with psoriasis. We
also measured IL-36g expression in a range of other skin
pathologies, including fungal infection, lichen planus,
systemic-, subacute cutaneous-, and chronic discoid lupus
erythematosus, all of which showed expression levels less than
the cutoff level of 214 pg/mg total protein (data not shown).
Both CCL27 and CCL17 have been suggested as potential
biomarkers for AD.5 CCL17 preferentially attracts IL-4/IL-13–
producing lymphocytes, whereas CCL27 is involved in the
homing of memory T cells to the skin.6 Epidermal tape stripping
demonstrated CCL17, but not CCL27, to be of value in
identifying AD (Fig 1, C). CCL27 levels were increased in both
psoriatic and AD lesions. In those cases in which CCL17 was
detectable, it pointed to an underlying AD inflammation (AUC,
0.79; SE, 0.058; 95% CI, 0.676-0.903). However, unlike
IL-36g, which was detectable in all psoriatic lesions tested, a
significant number of AD samples (25%), as well as 57.4% of
psoriatic samples, did not show any measurable CCL17.
The patient cohort (see Table E1 in this article’s Online
Repository at www.jacionline.org) included in our analysis
showed prototypic plaque psoriasis or AD. However, to further
illustrate the potential of tape-collected IL-36g as a diagnostic
approach for psoriasis, we investigated clinical cases of unclear
diagnosis. In each case the diagnostic value of IL-36gwas correct
when including dermatohistopathologic results. As an example,
we show 2 clinical cases (for details, see the Methods section in
this article’s Online Repository).
The first case was given a clinical diagnosis of and treated for
palmoplantar eczema in our dermatology department. However,
analysis of tape stripping showed IL-36g levels of 960 pg/mg total
protein, which are indicative of psoriasis. This fact and
subsequent dermatohistopathologic analysis and changes in
clinical features were supportive of a corrected diagnosis to that
of psoriasis (Fig 2, A).
The other case was a patient with symptoms of joint pain in
addition to erythrosquamous skin lesions. For the referring
rheumatologist, a confirmation of these skin lesions as psoriasis
would guide future diagnostic and treatment pathways in the
direction of psoriatic arthritis. However, tape stripping did not
confirm psoriatic inflammation, and the diagnosis for the skin
lesions was confirmed to be chronic eczema (Fig 2, B).
Numerous soluble mediators, cell-surface molecules, and
intracellular proteins have been described previously to be
upregulated in psoriatic lesions.2 In our noninvasive approach
we could confirm that levels of the neutrophil chemoattractants
IL-8 and CXCL1,7 as well as CCL20, the chemoattractant for
IL-17–producing cells, are increased in psoriatic compared with
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FIG 1. Comparison of IL-36g (A), CXCL1 (B), and CCL17 (C) levels in tape samples from psoriatic and atopic
eczema lesions. Tape stripping was performed on healthy volunteers and both lesional and nonlesional
(NL) skin from patients with clinically diagnosed AD or psoriasis (Pso). Tape-derived cytokine levels were
normalized to total protein content. ROC curves are depicted for all 3 parameters comparing samples
from patients with eczema and those with psoriasis. ****P < .0001.
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LETTERS TO THE EDITOR 989eczema lesions. Contrary to work showing reduced expression of
CCL27 in patients with psoriasis8 and the value of CCL27 as a
biomarker for AD,9 we did not find significant differences in
the amount of this chemokine. The differences between our
findings and those of some others is likely to be due to the method
of sampling.
In conclusion, although the effects of other factors, such as
systemic and topical therapeutics, age, sun exposure, and lesion
chronicity, need to be investigated in future studies, the resultspresented here confirm4 IL-36g to be a robust, specific,
and reliable biomarker for psoriatic inflammation that
outperforms previously reported biomarkers and is likely to
withstand all challenges in real-life primary and secondary
dermatologic care.
We thank the patients and volunteers who agreed to participate in the study.
We especially thank Jennifer Ott, Fiazia Ahmed, Rebecca Johnston, and Julie
Bush for patient identification and clinical trial management.
FIG 2. Tape stripping for the diagnosis of difficult clinical cases. Shown are pictures of 2 clinical
presentations in which the clinical diagnosis was unclear or challenging. Based on an IL-36g cutoff level
of 214 pg/mg total protein, tape stripping results indicated psoriatic inflammation for case A but not case B.
Histopathologic examination confirmed the results. A, Palmar psoriasis was misdiagnosed initially as
hand eczema. B, Chronic eczema. For further details on Fig 2, see this article’s Online Repository at
www.jacionline.org.
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with atopy, asthma, and leukemiaTo the Editor:
The phenome-wide association study (PheWAS) is a new,
validated, reverse genetics approach that associates genetic
variants of interest with phenotypes by linking a database of
deidentified genotyping to a broad range of electronic medical
record–derived clinical phenotypes.1 Although the more common
genome-wide association study (GWAS) is useful in identifying
genetic polymorphisms that may relate to one particular disease
phenotype, PheWAS’s ability to evaluate these polymorphisms
against an entire database of clinical phenotypes greatly expands
the scope of genomic association research. Using a PheWAS, one
is able to examine polymorphisms detected in the context of a
disease to not only confirm this established association with
greater certainty, but one may uncover links to entirely new
phenotypes that had not been previously considered or
investigated at the genetic level.1
IL-33 is one of the most consistently associated gene
candidates for asthma identified by GWASs in diverse ethnic
groups.2 IL-33 is a central mediator of both innate- and adaptive
immunity–regulated allergic inflammation in the lung.3,4 The
primary binding partner of IL-33, ST2, is a member of the IL-1
receptor family that is expressed on a number of immune cells,
including ILC2, CD41 TH2 cells, mast cells, and eosinophils.
5
GWASs investigating polymorphisms related to asthma have
identified a number of single nucleotide polymorphisms (SNPs)
in the ST2 receptor gene.6,7 We sought to investigate these
polymorphisms to assess the role of ST2 signaling in other,
non–asthma-related allergic diseases. In addition, we hoped to
identify new diseases in which genetic links to the ST2 receptor
had not been reported. We performed a PheWAS on 15 ST2
genetic variants implicated in asthma to assess their associationswith other allergic and nonallergic diseases. The Exome
BeadChip that we used to perform the PheWAS genotyped 38
variants in IL1R1. We only included variants with a minor allele
threshold (mean allele frequency [MAF]) of greater than 1%; this
filtering is necessary to support a PheWAS analysis using a
logistic regression. The PheWAS used a cohort of 36,400 adult
(age > 18 years) subjects who had genotyping on Illumina
HumanExome BeadChip version 1.1 and available electronic
health record (EHR) data from the Vanderbilt BioVU DNA
biobank that was ascertained previously for 5 different criteria:
(1) eligibility as case or control in 1 of 31 pharmacogenetic
studies, (2) available longitudinal data with primary care visits,
(3) presence in the cancer registry, (4) old age with longitudinal
data, and (5) presence of rare diseases or conditions ascertained
via billing codes. Of the 15 SNPs, 6 had MAFs greater than 1%
in the total cohort population, rendering them sufficiently
powered for further analysis.1 All these 6 SNPs are in the ST2
gene (human chromosome 2q11.2).6 The PheWAS yields results
as a list of phenotype International Classification of Diseases,
Ninth Revision (ICD-9) codes that best associated with each
particular SNP.
Our study revealed that the minor allele of ST2 SNP rs1041973
associated with allergic conjunctivitis (odds ratio [OR]5 1.27), an
allergic disease that had not been linked genetically in the context
of IL-33/ST2 signaling. We further demonstrate that the minor
allele of rs1041973 exhibits an inverse association with
eosinophilia, as indicated by an OR of less than 1 (0.686;
Table I). In addition, the PheWAS confirmed the previously
reported inverse relationship of 5 ST2 SNPs with asthma
(rs10192036: OR 5 0.876; rs1041973: OR 5 0.505; rs4988956:
OR 5 0.876; rs10192157: OR 5 0.876; rs10206753:
OR5 0.876), and it confirmed the formerly identified association
of rs1420101 (OR 5 1.20) with asthma.6,7 We calculated the
pair-wise linkage disequilibrium for each of the 6 variants tested
and found that the minor alleles of rs10192036, rs10206753,
rs4988956, and rs10192157 are in perfect linkage (r2 5 1). For
this reason, the associations of these 4 SNPs are reported under
only rs4988956. These genomic investigations with study
populations entirely separate from our own provide ORs in similar
directions for all 6 SNPs investigated in this study, confirming the
previously described association of each.6,7 This further supports
the validity of our method by demonstrating that genetic and
phenotypic data from Vanderbilt University Medical Center
patients is representative of national and international populations.6
Finally, the PheWAS uncovered a novel association of 2 SNPs in
the ST2 gene with various forms of leukemia (Table II). The minor
allele of the SNP rs1420101 associated with leukemia and acute
myeloid leukemia, whereas the minor allele of rs1041973
associated with leukemia, acute myeloid leukemia, and acute
lymphoid leukemia.
The results of this study inform our understanding of the ST2
pathway as it relates to other, nonasthmatic forms of allergic
disease. We are also the first to identify rs1041973 as a genetic
variant that associates inversely with eosinophilia. In an analysis
of peripheral blood eosinophilia for eosinophilia-associated
rs1041973 cases and controls, there was a significant increase
in the maximum-recorded percentage of peripheral blood
eosinophilis in cases (13.5%) compared with controls (3.4%;
P 5 3.15 3 102165; see Table E1 in this article’s Online
Repository at www.jacionline.org). Because SNPs examined
in this study were originally identified in a GWAS as relevant
METHODS
Patients
Patients with a clinical diagnosis of plaque psoriasis or AD presenting with
‘‘typical’’ morphology, as diagnosed by consultant dermatologists, were
included in the study. Hanifin and Rajka diagnostic criteria were followed
for eczema, and diagnosis of plaque psoriasis was based on traditional pattern
recognition combined with patient history. Patients’ demographics are shown
in Table E1.
This study was approved by NRES Committee North East-York (ILTIPP
study: REC 14/NE/1199, ALPHA study: REC 14/YH/1259) and for
recruitment of volunteers by the ethics committee of the University of Leeds
(BIOSCI 14-001). All participants provided written informed consent before
participation.
Overall disease activity differed significantly and was not collected for
analysis because the focus was on the individual lesion. A local lesion severity
score was assessed based on Psoriasis Activity and Severity Index items
(covering the range of 0-4) by specialist dermatologists before sample
collection (see Table E2). Patients receiving systemic immunomodulatory
therapy or biologics were excluded apart from 1 patient receiving anti–
TNF-a therapy (etanercept), which had lost efficacy, and 1 patient receiving
low-dose acitretin therapy. Where possible, preference was given to patients
who have not used topical corticosteroids in the sampled area for at least
48 hours. In the eczema group patients were considered atopic if presenting
with clinical symptoms of immediate-type reactions to allergens and/or the
presence of specific IgE, as measured by a routine RAST in serum samples.
Samples
Tape stripping was performed on lesional and nonlesional skin (ventral
forearm) at routine dermatology and combined dermatology/rheumatology
clinics and processed by using an improved tape-stripping protocol based on
previously published methodology.E1,E2 D-Squame adhesive discs of 3.8 cm2
(CuDerm, Dallas, Tex) were used. Choice of sample site was guided by loca-
tion of lesions, but preference was given to the hands, arms, and upper trunk
area. Only nonerosive nonoozing lesions were tape stripped. The first tape
was discarded, and 10 subsequent tapes from the same location were collected
and immediately stored on dry ice for transportation or stored at2808C until
protein was extracted.
Protein extraction and concentration determination
Frozen tapes were transferred into 1.5 mL of lysis buffer (20 mmol/L Tris
[pH 7.4], 150 mmol/L NaCl, 1% Triton X-100, 5 mmol/L EDTA, and 13
protease inhibitor cocktail; Roche, Welwyn Garden City, United Kingdom).
Tubes containing tapes were left on ice for 30minutes before sonication cycles
of 3 times 20 seconds with a 20-second interval on ice between each
sonication. The extracts were centrifuged at 15,000g for 10 minutes, and the
protein concentration of each sample was determined by using the bicincho-
ninic acid assay (Life Technologies, Paisley, United Kingdom).
Generation of human IL-36g ELISA and
measurement of soluble mediators
To generate mAbs against human IL-36g, C57B/6mice or Sprague Dawley
rats were immunized twice with recombinant IL-36g Ser18-Asp169 first in
complete Freund adjuvant and subsequently in incomplete Freund adjuvant.
Aqueous boosts 3 to 4 days before fusions were administered intraperitoneally
with the same protein in PBS. Spleen cells were fused with the myeloma cell
lines Y3-AG 1.2.3 (rat) or SP2/O-Ag14 (mouse), as appropriate, by using a
method similar to the original described byKohler andMilstein.E3 Hybridoma
supernatants were screened against IL-36g– or appropriate control–coated
immunosorbent plates, and selected fusion wells were cloned twice to ensure
monoclonality.
Characterization of purified mAbs indicated that the antibody generated by
mouse hybridoma B5A2 performed effectively as a capture antibody, and the
antibody generated by rat hybridoma HCL17 performed effectively as a
detection antibody by using sandwich ELISA. Antibodies were subsequently
purified with either protein A or protein G affinity chromatography. The
antibody HCL17 was then biotinylated with EZ link NHS-LC-biotin (Thermo
Scientific, Waltham, Mass), according to the manufacturer’s instructions.
ELISA
Immunosorbent 96-well ELISA plates (Nunc Life Technologies, Paisley,
UnitedKingdom)were coatedwith 2mg/mLB5A2 capture antibody in PBS at
48C overnight. Plates were then washed 3 times with 0.1% Tween 20/PBS and
blocked for 1 hour in 2% BSA in 0.1% Tween-20/PBS. Samples were
incubated subsequently for 1 hour at room temperature before washing and
incubation with 1 mg/mL HCL17 biotinylated detection antibody for 1 hour.
Plates were then washed and incubated with streptavidin–horseradish
peroxidase (BioLegend, London, United Kingdom) for 20 minutes. After
washing, TMB was used as a chromogenic substrate (Thermo Scientific). The
reaction was stopped with 2N H2SO4, and OD was measured at 450 nm.
A standard curve was obtained from a 7-point serial dilution of protein stan-
dard and used to calculate IL-36g concentrations. CCL27 from the tape-
stripping samples was quantified by means of ELISA (Bio-Techne, Abingdon,
United Kingdom), according to the manufacturer’s protocol.
Multiplex bead-based quantification assays
Cytokines (CCL20, CXCL1, and IL-8) from tape-stripping samples were
measured by using bead-based immunoassay purchased fromBioLegend. The
assay was carried out according to the manufacturer’s instructions, and
fluorescent beads were acquired by using flow cytometry (LSRII; BD
Biosciences). The results were analyzed with LEGENDplex analysis software
(BioLegend).
Histopathology
Routine diagnostic punch biopsy specimens were taken from lesional skin,
fixed in 10% formaldehyde, embedded in paraffin, stained with hematoxylin
and eosin, and evaluated by experienced dermatopathologists.
Statistical analysis
Results were analyzed with GraphPad Prism software, version 7.00
(GraphPad Software, La Jolla, Calif). Results for each group are depicted as
means 6 SDs. Data were analyzed by using 1-way ANOVA followed by the
Tukey multiple comparison test to determine statistically significant differ-
ences between groups. Sensitivity and specificity analysis was performed by
using ROC curve analysis. The optimal cutoff level was determined according
to the Youden index.
Clinical cases
Case A, a 61-year-old male patient, received a diagnosis of chronic
palmoplantar eczema based on clinical appearance and symptoms (Fig 2, A).
Therewere no signs of eczema or psoriasis elsewhere on the body. The patient
had no personal history of atopy; family history was positive for allergic
asthma and negative for psoriasis. Patch testing revealed a positive reaction
to methylchloroisothiazolinone, exposure to which the patient avoided subse-
quently. The patient’s total IgE level was 767 kU/Lwithout detectable specific
IgE to inhaled allergen mix. Mycology microscopy and culture results were
negative for fungal infection. The patient showed very little to no benefit
from immersion PUVA therapy and presented little response to 30 mg/
d oral alitretinoin. During the disease course, lesions gained a slightly different
appearance as coarser scales developed. Tape-stripping samples were taken
before a diagnostic biopsy was obtained from a right palmar lesion. Results
were highly suggestive of the diagnosis of psoriasis, with significantly
enhanced levels of IL-36g (IL-36g, 959.3 pg/mg; CXCL1, 15.9 pg/mg; and
IL-8, 29.2 pg/mg; CCL17 was not detected). Histopathologic examination
from the same site confirmed the diagnosis of psoriasis. Subsequently,
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re-examination of the patient revealed some nail pitting (Fig 2, A), a symptom
associated with psoriatic inflammation.
Case B, who was referred by the rheumatology department, presented with
unclassified polyarthralgia and some skin symptoms. The presence of
relatively well circumscribed margins and a thick adherent scale included
psoriasis as a differential diagnosis (Fig 2, B). However, low expression of IL-
36g in tape-stripping samples did not suggest psoriasis (IL-36g, 25.2 pg/mg;
CXCL1, 0.12 pg/mg; and IL-8, 0.25 pg/mg; CCL17 levels were less than detec-
tion levels). Subsequent histopathologic examination confirmed the diagnosis
of eczema.
Detailed legend of Fig 2
A, Upper pictures, Typical clinical signs of eczema: palmar erythema with
moderate infiltration of the skin, deeply seated vesicles with discrete erosions,
and fine scaling associated with intense itchiness. Lower pictures, The same
patient 3 months later presented a change in clinical phenotype with the pres-
ence of rare intact pustules accompanied by accentuated scaling and typical
nail changes showing pitting and ridging. Histopathologic examination shows
regular epidermal hyperplasia, with clubbing and anastomosis of the elon-
gated rete ridges associated with suprapapillary plate thinning. Mild, patchy,
perivascular infiltrate composed of lymphocytes without eosinophils and
mild exocytosis is present. The granular layer is still present as well. However,
there is some parakeratosis in which collections of neutrophils are identified
(hematoxylin and eosin stain; high-power magnification3400).B,Upper pic-
tures, Relatively well-demarcated, slightly erythematous, intensely itchy
lesion covered by thick adherent scales in the left lateral supramalleolar local-
ization of a 51-year-old female patient. Histopathologic examination showed
irregular epidermal hyperplasia in association with hyperkeratosis and hyper-
granulosis. Patchy epidermal spongiosis with focal lymphocytic exocytosis
can be seen. There is no club-shaped elongation of the rete ridges, and neutro-
phils are not identified. The features are in favor of those of a lichenified
eczema (hematoxylin and eosin stain; high-power magnification 3400).
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TABLE E1. Demographic characteristics of patients
Patients
with AD
Patients with
psoriasis
Healthy
subjects
Sex
Male 28% 51% 38%
Female 72% 49% 62%
Age (y)
Mean 42 47 37
Range 21-69 18-67 25-50
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TABLE E2. Comparison of local severity scores of patients with
AD and psoriasis
Patients with AD Patients with psoriasis
Mean erythema score 2.40 2.61
Mean infiltration score 2.37 2.14
Mean scaling score 1.88 2.18
Mean total lesion score 2.23 2.31
A local severity score was determined by experienced dermatologists for all patients
with eczema and psoriasis included in the study.
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